Compare BridgeBio Pharma Inc (BBIO) vs Funko Inc (FNKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Funko Inc — how do they compare? BridgeBio Pharma Inc trades at $82.09 (market cap $16.46B), while Funko Inc trades at $5.68 (market cap $310.19M). The key difference: BridgeBio Pharma Inc is far larger — about 53.1× Funko Inc's market cap, and Funko Inc is trading nearer its 52-week high, BridgeBio Pharma Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | FNKO | |
|---|---|---|
Market Cap | $16.46B | $310.19M |
Sector | Health | Consumer Staples |
52-Week High | $90.17 | $5.88 |
52-Week Low | $44.81 | $2.46 |
Enterprise Value | $18.02B | $555.22M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
FNKO trades at $5.69, up 1.97% with a bullish technical signal. Recent earnings beat expectations, yet the company reported a net loss of $67.36M in 2025. Revenue declined to $908.21M, but Q1 2026 showed improvement. Analyst consensus is mixed with 42.86% buy ratings. Cash flow trends are stabilizing, though negative profitability and high debt remain concerns.
Outlook hinges on execution of new product launches and cost management. Opportunities include brand strength and collectibles demand, but risks involve sustained losses, competitive pressure, and leverage. The stock presents a speculative growth play with significant turnaround requirements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Funko Inc
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →
